Actively Recruiting

Phase 3
Age: 2Years - 17Years
All Genders
ID03619850

A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

Led by AMAG Pharmaceuticals, Inc. · Updated on 2026-04-17

129

Participants Needed

21

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety, effectiveness, and pharmacokinetics of ferumoxytol compared to iron sucrose in children with chronic kidney disease (CKD) who have iron deficiency anemia (IDA) or are at risk of developing it. The study focuses on pediatric patients aged 2 to under 18 years and aims to better understand ferumoxytol's profile in this group. This Phase 3, randomized, open-label study involves multiple centers and approximately 125 participants. Participants will be randomly assigned in a 2:1 ratio to receive either ferumoxytol or iron sucrose. Those in the ferumoxytol group will get two intravenous infusions of 7.0 mg Fe/kg (up to 510 mg per dose), the first on Day 1 and the second 2 to 8 days later. Those receiving iron sucrose will have dosing based on dialysis status: hemodialysis-dependent patients receive 2 mg Fe/kg on consecutive dialysis sessions for 10 doses, and non-hemodialysis-dependent or peritoneal dialysis-dependent patients receive 4 mg Fe/kg up to three times per week for 5 doses, with total maximum doses capped at 1000 mg. The study lasts up to 7 weeks, including a 2-week screening period and a 5-week treatment period. Researchers will monitor hemoglobin changes, adverse events, and special safety concerns during 49 days of follow-up. Assessments include blood tests to measure hemoglobin and iron levels, safety evaluations, and pharmacokinetic and pharmacodynamic analyses. This helps determine how participants respond and tolerate the treatments over time.

CONDITIONS

Brief Title

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

Who Can Participate

Age: 2Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged 2 to under 18 years at time of consent
  • Has iron deficiency anemia defined by hemoglobin less than 12.0 g/dL and either transferrin saturation less than 40% or ferritin less than 100 ng/mL, or is at risk of developing iron deficiency anemia
  • Has chronic kidney disease defined as being on chronic hemodialysis, receiving chronic peritoneal dialysis, having an estimated glomerular filtration rate below 60 mL/min/1.73 m2, or having structural or functional kidney abnormalities lasting more than 3 months
  • For non-hemodialysis patients, has a documented history of unsatisfactory or intolerable oral iron therapy or oral iron is medically inappropriate
  • If sexually active and of childbearing potential, agrees to use effective birth control from at least 1 month before dosing until study completion
Not Eligible

You will not qualify if you...

  • Known allergic reactions to ferumoxytol or iron sucrose
  • History of allergy to intravenous iron
  • History of multiple drug allergies (more than 2)
  • Low systolic blood pressure below age-based thresholds
  • Hemoglobin less than or equal to 7.0 g/dL
  • Serum ferritin level greater than 600 ng/mL

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 5 weeks

Participants receive either two IV infusions of ferumoxytol or multiple doses of iron sucrose depending on their dialysis status.

Multiple visits over 5 weeks for infusions and assessments

Trial Site Locations

Total: 21 locations

1

Memorial Healthcare System

Hollywood, Florida, United States, 33021

Not Yet Recruiting

2

Wayne State University

Detroit, Michigan, United States, 48201

Active, Not Recruiting

3

Children's Mercy Hospital

Kansas City, Missouri, United States, 64108

Actively Recruiting

4

The Feinstein Institute Medical Research Organization of Northwell Health, Inc.

Lake Success, New York, United States, 11042

Not Yet Recruiting

5

Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)

New York, New York, United States, 10029

Active, Not Recruiting

6

Montefiore Medical Center (MMC) - The Children's Hospital at Montefiore (CHAM)

The Bronx, New York, United States, 10467

Actively Recruiting

7

Akron Nephrology Associates, Inc.

Akron, Ohio, United States, 44302

Actively Recruiting

8

West Virginia University

Morgantown, West Virginia, United States, 26506

Actively Recruiting

9

Semmelweis Egyetem - Altalanos Orvostudomanyi Kar (SE AOK) - I. sz. Gyermekgyogyaszati Klinika

Budapest, Hungary

Actively Recruiting

10

University Of Szeged

Szeged, Hungary

Actively Recruiting

11

Hospital of Lithuanian University of Health Sciences Kauno klinikos

Kaunas, Lithuania

Not Yet Recruiting

12

Klaipeda Children's Hospital

Klaipėda, Lithuania

Active, Not Recruiting

13

Vsl Vilniaus Universiteto Vaiku Ligonine (VUVL) (Vilnius University Children's Hospital)

Vilnius, Lithuania

Not Yet Recruiting

14

Instituto Mexicano De Trasplantes S.C

Cuernavaca, Mexico

Actively Recruiting

15

JM Research, SC

Cuernavaca, Mexico

Active, Not Recruiting

16

Hospital Civil de Guadalajara Fray Antonio Alcalde

Guadalajara, Mexico

Actively Recruiting

17

Instituto Nacional de Pediatria (INP) (National Institute of Pediatrics)

Mexico City, Mexico

Actively Recruiting

18

Uniwersytecki Szpital Kliniczny Im. Zamenhofa w Bialystoku

Bialystok, Poland

Not Yet Recruiting

19

Specjalistyczne Gabinety Sp. z o.o

Krakow, Poland

Active, Not Recruiting

20

University Children Hospital

Krakow, Poland

Not Yet Recruiting

21

Polish Mother's Memorial Hospital Research Institute

Lodz, Poland

Not Yet Recruiting

Loading map...

Research Team

C

Clinical Trial Interest

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here